Epirubicin cardiotoxicity: A study comparing low- with high-dose-intensity weekly schedules
Supportive Care in Cancer, ISSN: 0941-4355, Vol: 4, Issue: 4, Page: 308-312
1996
- 11Citations
- 6Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations11
- Citation Indexes10
- 10
- CrossRef7
- Policy Citations1
- Policy Citation1
- Captures6
- Readers6
Article Description
Epirubicin is one of the less cardiotoxic alternatives to doxorubicin. We were interested in studying the cardiotoxic effect of the total cumulative dose, and weekly schedules of low compared to high dose intensity. Fifty-seven patients were treated with different epirubicin-containing regimens. We confirm the classical notion that total cumulative doses of less than 600 mg/m do not induce significant cardiotoxicity, whereas doses above 600 mg/m are associated with a trend towards cardiotoxicity. Patients receiving a high weekly dose intensity (> 40 mg/m), however, did have a significantly lower incidence of cardiotoxicity than those receiving a low dose intensity per week (< 40 mg/m) (22.8% versus 50%; P < 0.05). We identified the association of a dose intensity of more than 40 mg m/ week and a cumulative dose of 400-899 mg/m or a dose intensity of less that 40 mg m/week and a cumulative dose of less than 400 mg/m to have the lowest incidence rate of cardiotoxicity. We conclude from this study that epirubicin in weekly schedules of high dose intensity is not more cardiotoxic than in weekly schedules of low dose intensity.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0030188095&origin=inward; http://dx.doi.org/10.1007/bf01358886; http://www.ncbi.nlm.nih.gov/pubmed/8829311; http://link.springer.com/10.1007/BF01358886; http://www.springerlink.com/index/pdf/10.1007/BF01358886; http://www.springerlink.com/index/10.1007/BF01358886; https://dx.doi.org/10.1007/bf01358886; https://link.springer.com/article/10.1007/BF01358886
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know